Deals, Partnering

Crucell N.V. reaches agreement with Sanofi Pasteur on programs in the field of paediatric and respiratory vaccines

Posted on 09 July 2010

Tags: ,

Dutch biopharmaceutical company Crucell N.V, today announced that Crucell and sanofi pasteur reached an agreement on a series of transactions to restructure their long standing partnership.

Crucell will waive its right to terminate an existing license agreement between Crucell Switzerland and sanofi pasteur's subsidiary Shantha Biotechnics Limited (Shantha) for the development of paediatric vaccines, based on Haemophilus influenzae b. This termination right was triggered by the acquisition of Shantha by sanofi pasteur in July 2009.

More on the Crucell/sanofi pasteur partnership (link no longer available)

Print Friendly, PDF & Email

Leave a Reply